Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted SBRT and toripalimab de-intensification trial in HPV-positive oropharyngeal carcinoma
ChiCTR2600133542Phase 2Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab in oropharyngeal squamous cell carcinoma (3 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival. Started Dec 2024; status: completed.
02
Drugs
toripalimab
03
Conditions
oropharyngeal squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2600133542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133542.